A New Challenging and Promising Era of Tyrosine Kinase Inhibitors | Zendy

J. Jean Cui | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A New Challenging and Promising Era of Tyrosine Kinase Inhibitors

Author(s) -

J. Jean Cui

Publication year - 2014

Publication title -

acs medicinal chemistry letters

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.065

H-Index - 66

ISSN - 1948-5875

DOI - 10.1021/ml500091p

Subject(s) - tyrosine kinase , protein tyrosine kinases , kinase , drug resistance , medicine , drug discovery , drug , bioinformatics , drug development , cancer , cancer research , signal transduction , computational biology , pharmacology , biology , microbiology and biotechnology , genetics

Protein kinases are key regulators that govern complex cellular processes. Dysregulation of kinase signaling is associated in many human diseases, particularly cancers and developmental and metabolic disorders. Tyrosine kinase inhibitors have achieved great success in molecular targeted therapies for cancer and now is expanding to other therapeutic areas. The onset of drug resistance to prolonged TKI treatment brings new challenges in TKI drug development. The deep understanding of disease pathologies related to TKs and drug resistance mechanisms will generate new waves for seeking highly selective, potent, and safe TKIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research